DOCSLIB.ORG

Neuroendocrine and Cardiovascular Effects of MDE in Healthy Volunteers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroendocrine and Cardiovascular Effects of MDE in Healthy Volunteers NEUlIOPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 187 Neuroendocrine and Cardiovascular Effects of MDE in Healthy Volunteers Euphrosyne Gouzoulis, M.D., Ulrich von Bardeleben, M.D., Armin Rupp, KIlrl-Arthur Kovar, Ph.D., and Leopold HermIe, M.D. Thedrug 3,4-methylenedioxyethamphetamine ([MDE] every 20 minutes until 5:00 P.M. Administration of also known as "Eve") is a less toxic analog of 3,4- MDE was followed by statistically significant long-lasting mtthylenedioxymethamphetamine (also known as increases of serum cortisol, PRL, systolic blood pressure, "Ecstasy") with similar psychotropic effects in humans. and heart rate, and by a trend toward blunting of GH In a double-blind placebo-controlled, cross-over study we secretion. The neuroendocrine and cardiovascular effects IIlministered 140 mg of MDE or placebo orally to eight of MDE are comparable to those of other phenethyl­ htaIthy male volunteers at 1:30 P.M. Serum cortisol, amines with the exception of the effect on GH secretion. prolactin (PRL), and growth hormone (GH) levels, as lNeuropsychopharmacology 8: 187-193, 1993J wellas blood pressure, and heart rate were measured KEY WORDS: MDE; MDMA; Cortisol; Prolactin; out distortion of sensory perception and thought and Growth honnone; Cardiovascular effects without marked stimulation (Greer and Tolbert 1986, 1990; Peroutka et al. 1988). Pharmacologic studies on The phenethylamines 3,4-methylenedioxymetham­ the structure-activity relationships of MDMA and phetamine ([MDMA]also known as "Ecstasy") and 3,4- related compounds supported the view that MDMA methylenedioxyethamphetamine ([MDE] also known and MDE might constitute a new psychoactive sub­ as"Eve") are chemically related to amphetamines and stance class, which was named the "entactogens" psychedelics like mescaline and methylenedioxyam­ (Nichols 1986; Nichols and Oberlender 1990). phetarnine(MDA) (Oimko et al. 1987). However, they The reasons for the public controversy about werepurported to exert unique psychotropic effectsin MDMA are its growing popularity and illegal abuse dur­ humans,diff erentiating them from the aforementioned ing the past years (Seymour 1986; Beck and Morgan chemically related substances (Shulgin and Nichols 1986; Beck 1990), its reported medical usefulness as an 1978; Shulgin 1986). Both MDMA and MDE were adjunct in insight-oriented psychotherapy (Grinspoon reportedto possess antidepressant and anxiolytic prop­ and Bakalar 1986; Greer and Tolbert 1990), and its pos­ erties and to evoke a well-controllable emotional ex­ sible neurotoxicity in humans (Price et al. 1989; Grob perience with relaxation, peaceful feelings, increased et al. 1990). In experimental animals, MDA and MDMA empathy, and a drop in fear responses, mostly with- were shown to exert neurotoxic effects on central serotonergic neurons resulting in degeneration of axon terminals (Ricaurte et al. 1985, 1988; Battaglia et al. From the Department of Psychiatry, University of Freiburg (EG, 1988b, 1990; Insel et al. 1989; Gibb et al. 1990; Schmidt UV,lli), and Instituteof Pharmaceutics, University of Tiibingen(AR, K·AJ(), Federal Republic of Germany. et al. 1990). It is not yet clear whether this fmding has Address reprint requests: Euphrosyne Gouzoulis, M.D., Depart­ a relevance for humans (Peroutka et al. 1987; Price et ment ofPsychiatry, Medical Faculty of the RWTH, Pauwelsstrasse al. 1989; Grob et al. 1990), but it played an important ll, 0·5100 Aachen, Federal Republic of Germany. ReceivedAugust 5, 1991; revised March 11, 1992and June 10, 1992; role for the assignment of MDMA to Schedule I status KteptedJune 16, 1992. by the Drug Enforcement Agency in 1985. After the C 1993 American College of Neuropsychopharmacology Publishedby Elsevier Science Publishing Co., Inc. 655A venue of the Americas, New York, NY 10010 0893-133X/93/$6.00 188 E. Gouzoulis et al. NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 scheduling of MDMA its N-ethyl analog, MDE ("Eve"), MATERIALS AND METHODS became more popular and served as an MDMA substi­ Subjects tute for recreational use (Beck 1990). The action of MDE is supposed to be more subtle and shorter (3 to 4 hours), Eight physically and mentally healthy, drug-free, male but otherwise very similar to the action of MDMA. volunteers (all academics: seven physicians, one en­ Studies of animal behavior underlined the similarity be­ gineer), ranging in age from 29 to 50 years (mean 38 tween MDE and MDMA (Boja and Schechter 1987). years) were included in a randomized double-blind Neurochemical studies showed that MDE is far less toxic placebo-controlled cross-over study. They gave in­ than MDA and MDMA (Schmidt 1987; Ricaurte et al. formed written consent and did not receive any pay­ 1987; Stone et al. 1987; Gibb et al. 1990). ment for participating in the study. Three to 7 days prior Both MDMA and MDE show high affinities at ser­ to the trial they underwent extensive physical and men­ otonin (5-HT) uptake sites, and lower affinities at nor­ tal examinations (medical history, physical examina­ epinephrine and dopamine (DA) uptake sites of cen­ tion, electroencephalography, electrocardiography tral neurons (Battaglia et al. 1988a). They are taken up (ECG), freepsychiatric interview, structured clinical in­ into the neurons and cause release and reuptake in­ terview according to DSM-III-R, Freiburger Personal­ hibition of the endogenous transmitters (Johnson et ity Inventory (FPI), State-Trait Anxiety Inventory X2, al. 1986,1988; Steele et al. 1987; Schmidt 1987). In ad­ and a questionnaire for vegetative lability). The exclu­ dition, the substances have low affinities at 5-HT2-, sion criteria were any signifIcant physical illness requir­ 5-HT1-, and D2-binding sites, but those seem to be ing therapy, any mental illness, and alcohol or sub­ less important for the drugs' action (Lyon et al. 1986; stance abuse at present or in the past, as defIned by Battaglia et al. 1988a). DSM-IIJ criteria. Mental illness in fIrst degree relatives In our literature review, we found only anecdotal was also an exclusion criterion. No volunteer had previ­ reports about the psychotropic effects and no human ous experience with MDE. One subject reported one experimental data on neurobiologic effectsof the drugs. experience with MDMA 2 years before. Another sub­ The aim of our investigation was to study the phar­ ject reported sporadic experience with cannabis about macokinetics and metabolism, as well as the psycho­ 10 to 15 years before, and one experience with MDMA logic and neurobiologic effects(endocrine, polysomno­ 1.5 years before. A third subject reported sporadic graphic, cardiovascular) of MDE in healthy volunteers, experience with cannabis and one experience with and to attempt a characterization of the substance. In D-lysergic acid (LSD) about 7 to 10 years before. All this paper, we present the neuroendocrine and cardio­ psychometric measurements were within normal vascular studies. range, except for the FPI dimension "openness," in Studies of the neuroendocrine effects of centrally which a higher than average mean score was obtained. acting drugs may contribute to the pharmacologic char­ The complete psychometric data are reported in a sep­ acterization of these substances. Numerous studies arate paper (HermIe et al., 1993). demonstrate that 5-HT and 5-HT agonists stimulate hypothalamic neurons that regulate adrenocorticotropic Substances hormone and corticosterone secretion from the pitu­ itary and adrenocortex, respectively (Fuller 1981). The The MDE used in this study was synthesized at the In­ secretion of prolactin (PRL) from the anterior pituitary stitute of Pharmaceutics, University of Tiibingenand isregulated by inhibitory tuberoinfundibular dopamin­ was obtained in the form of 70 mg capsules. Placebo ergic neurons and by an indirect stimulatory serotoner­ capsules were obtained from the same institute. The gic mechanism (Gudelsky 1981; Van de Kar et al. 1985a). volunteers received 140 mg of MDE, a dose commonly The secretion of growth hormone (GH) is stimulated taken for recreational use (Greer and Strassman 1985; by enhanced catecholaminergic and serotonergic trans­ Beck and Morgan 1986; Seymour 1986; Peroutka 1990). mission (Brown et al. 1978; Matussek 1988; Meltzer and Nash 1988). Both MDMA and MDE provoke release and Experimental Design reuptake inhibition of 5-HT in the central nervous sys­ tem (CNS), and to a lesser extent also of norepineph­ Subjects arrived at the hospital at 12:00 A.M. They re­ rine and dopamine (Johnson et al. 1986,1988; Steele et ceived a standardized calorie- and electrolyte-balanced al. 1987). Thus, one might expect that the acute adminis­ diet for lunch, and then entered the laboratory. Sub­ tration of MDMA or MDE in healthy volunteers would jects had to stay awake and supine with head and up­ increase the secretion of corticosterone, GH, and prob­ per trunk elevated on a bed in a single sound-isolated ably PRL, resulting in elevated plasma levels. Such room during the trial while they were observed by a fIndingswould also be in line with animal experimen­ video camera with a monitor located in the neighbor­ tal data showing an enhancement of cortisol and PRL ing laboratory unit. An intravenous catheter was placed secretion induced by MDMA (Nash et al. 1988). in a forearm vein between 1:15 P.M. and 1:25 P.M. and NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO. 3 Endocrine Effects of MDE 189 was kept open during the trial by a slow infusion of macoat, Dade). Concentrations of PRL and GH were salineso lution. The cuffof the sphygmomanometer and measured by immunoradiometric assays (Irma, IDS). ECG rate meter for registration of blood pressure and The coefficients of variation were as follows. For cor­ heartrate was placed round the other forearm. The cath­ tisol: 4.4 to 7.9 (within assay) and 5.2 to 9.7 (between eter and the sphygmomanometer were connected to assay); for PRL 2.7 to 4.8 (within assay) and 3.9 to 7.3 longtubes that passed through an opening in the wall (between assay); and for GH 3.7 to 5.7 (within assay) into the adjacent laboratory.
Load more

Recommended publications
  • From Sacred Plants to Psychotherapy
    From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine).
    [Show full text]
  • Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters
    Year of edition: 2018 Authors of the text: Marc Aixalà & José Carlos Bouso Edition: Alex Verdaguer | Genís Oña | Kiko Castellanos Illustrations: Alba Teixidor EU Project: New Approaches in Harm Reduction Policies and Practices (NAHRPP) Special thanks to collaborators Alejandro Ponce (in Peyote report) and Eduardo Carchedi (in Kambó report). TECHNICAL REPORT ON PSYCHOACTIVE ETHNOBOTANICALS Volumes I - II - III ICEERS International Center for Ethnobotanical Education Research and Service INDEX SALVIA DIVINORUM 7 AMANITA MUSCARIA 13 DATURA STRAMONIUM 19 KRATOM 23 PEYOTE 29 BUFO ALVARIUS 37 PSILOCYBIN MUSHROOMS 43 IPOMOEA VIOLACEA 51 AYAHUASCA 57 IBOGA 67 KAMBÓ 73 SAN PEDRO 79 6 SALVIA DIVINORUM SALVIA DIVINORUM The effects of the Hierba Pastora have been used by Mazatec Indians since ancient times to treat diseases and for divinatory purposes. The psychoactive compound Salvia divinorum contains, Salvinorin A, is the most potent naturally occurring psychoactive substance known. BASIC INFO Ska Pastora has been used in divination and healing Salvia divinorum is a perennial plant native to the Maza- rituals, similar to psilocybin mushrooms. Maria Sabina tec areas of the Sierra Madre Oriental Mountains of Mexi- told Wasson and Hofmann (the discoverers of its Mazatec co. Its habitat is tropical forests, where it grows between usage) that Salvia divinorum was used in times when the- 300 and 800 meters above sea level. It belongs to the re was a shortage of mushrooms. Some sources that have Lamiaceae family, and is mainly reproduced by cuttings done later feldwork point out that the use of S. divinorum since it rarely produces seeds. may be more widespread than originally believed, even in times when mushrooms were abundant.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans
    molecules Review Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Paul Cumming 1,2,* , Milan Scheidegger 3 , Dario Dornbierer 3, Mikael Palner 4,5,6 , Boris B. Quednow 3,7 and Chantal Martin-Soelch 8 1 Department of Nuclear Medicine, Bern University Hospital, CH-3010 Bern, Switzerland 2 School of Psychology and Counselling, Queensland University of Technology, Brisbane 4059, Australia 3 Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital of the University of Zurich, CH-8032 Zurich, Switzerland; [email protected] (M.S.); [email protected] (D.D.); [email protected] (B.B.Q.) 4 Odense Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark; [email protected] 5 Department of Nuclear Medicine, Odense University Hospital, DK-5000 Odense, Denmark 6 Neurobiology Research Unit, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark 7 Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, CH-8058 Zurich, Switzerland 8 Department of Psychology, University of Fribourg, CH-1700 Fribourg, Switzerland; [email protected] * Correspondence: [email protected] or [email protected] Abstract: Hallucinogens are a loosely defined group of compounds including LSD, N,N- dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), Citation: Cumming, P.; Scheidegger, which can evoke intense visual and emotional experiences. We are witnessing a renaissance of re- M.; Dornbierer, D.; Palner, M.; search interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. Quednow, B.B.; Martin-Soelch, C. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and Molecular and Functional Imaging ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or Studies of Psychedelic Drug Action in single photon emission computer tomography (SPECT).
    [Show full text]
  • Psychedelic Drugs
    108 PSYCHEDELIC DRUGS HENRY DAVID ABRAHAM UNA D. MCCANN GEORGE A. RICAURTE As defined in this chapter, the term psychedelic drugs includes 14.1%, and 7.2% of Danes reported the use of hallucino- both classic hallucinogens [i.e., indolalkylamines and phe- genic mushrooms (3). nylalkylamines, such as lysergic acid diethylamide (LSD) and In the United States, a survey of 633 undergraduates mescaline, respectively], ‘‘dissociative’’ drugs [i.e., arylcyclo- found that 23.8% had experimented with hallucinogenic hexamines, such as phencyclidine (PCP) and ketamine], and mushrooms, and 16.3% had had experience with LSD. substituted amphetamine analogues [i.e., phenylpropano- Among LSD users, 6.6% reported problems associated with lamines, such as 3,4-methylenedioxymethamphetamine LSD (Abraham and Koob, unpublished data). Of this group, (MDMA, ‘‘ecstasy’’)]. The use of psychedelic drugs dates 46.9% reported symptoms of hallucinogen persisting per- from the dawn of recorded history and continues today. ception disorder (HPPD), 37.5% described alcohol depen- Indeed, in Western culture, their use appears to be on the dence, 25% major depression, 18.8% persisting delusions, rise. Despite the longstanding popularity of psychedelic 15.6% panic attacks, and 12.5% auditory hallucinations. drugs, controlled research evaluating their effects in humans LSD use is most likely to occur between the ages of 18 and has been surprisingly scant, and data from preclinical studies 25. Use is more common in male Caucasians and Hispanics. have been largely limited to the last several decades. This Of note is that although the parents of LSD users tend to chapter reviews preclinical and clinical research involving be of a higher socioeconomic status, the users themselves indolalkylamines, arylcyclohexamines, and substituted am- exhibit an inverse relationship between LSD use and educa- phetamines, for which LSD, PCP, and MDMA are used as tional achievement (4).
    [Show full text]
  • PSYCHEDELIC PSYCHIATRY Substance Use Disorders: a Comprehensive Review and Update 2021
    PSYCHEDELIC PSYCHIATRY Substance Use Disorders: A Comprehensive Review and Update 2021 Franklin King IV, MD Director, Training and Education, Center for Neuroscience of Psychedelics Massachusetts General Hospital www.mghcme.org Disclosures “Neither I nor my spouse/partner has a relevant financial relationship with a commercial interest to disclose.” www.mghcme.org What are psychedelics? • Psychedelic, 1956 = “mind-manifesting” • Change in consciousness, often with profound, transformative experience of spiritual or mystical importance, and/or personal meaning • “Ego dissolution” – decreased boundary between self and world; increased connectedness • Increased sensory experiences: synesthesia, visual imagery and/or hallucinations www.mghcme.org What are psychedelics? • Tryptamines • (LSD, psilocybin, DMT/ayahuasca) • Phenethylamines • (mescaline, MDMA) • Ibogaine • Ketamine www.mghcme.org What are psychedelics? • Tryptamines • (LSD, psilocybin, DMT/ayahuasca) • Phenethylamines • (mescaline, MDMA) • Ibogaine • Ketamine www.mghcme.org I. PHARMACOLOGY, SAFETY AND TOXICITY www.mghcme.org Pharmacology • Acute effects: 6-12 hours (LSD), 4-6 hours (psilocybin, ayahuasca) • Primary psychedelic effect via 5HT-2A agonism • Blocked by ketanserin • Partial agonist at 5HT-1A • Increased cortical glutamate Preller, Elife 2018 www.mghcme.org Pharmacology • Tachyphylaxis occurs after 3-4 days of administration • Cross tolerance between compounds • Correlates with downregulation of 5-HT2A receptors in animal models • Implications for microdosing Nichols
    [Show full text]
  • The Long, Strange Trip of Mescaline
    BOOKS & ARTS COMMENT harmacologists gave mescaline a fair trial. In Pthe early and mid- twentieth century, it seemed more than plausible that the fash- ionable hallucinogen could be tamed into a therapeutic agent. Mescaline: A After all, it had pro- Global History found effects on the of the First human body, and had Psychedelic been used for cen- MIKE JAY turies in parts of the Yale University Press Americas as a gateway (2019) to ceremonial spiritual experience. But this psychoactive alkaloid never found its clinical indication, as science writer Mike Jay explains in Mescaline, his anthropologi- cal and medical history. In the 1950s, the attention of biomedical researchers abruptly switched to a newly synthesized molecule with similar hallucinogenic properties but fewer physical side effects: lysergic acid di ethylamide, or LSD. First synthesized by Swiss scientist Albert Hofmann in 1938, LSD went on to become a recreational drug of choice in the 1960s hippy era. And, like mescaline, it teased psychiatrists without delivering a cure. ANCIENT HISTORY Jay traces the chronology of mescaline use. The alkaloid is found in the fast-growing San Pedro cactus (Echinopsis pachanoi) that towers above the mountainous desert scrub of the Andes, and the slow-growing, ground-hugging peyote cactus (Lophophora williamsii) native to Mexico and the south- western United States. Archaeological evidence suggests that the use of these cacti in rites of long-vanished cultures goes back at least 5,000 years. Europeans first came across peyote after Spain conquered Mexico in the early six- teenth century. (It is mentioned, for instance, in a mammoth study, The General History of the Things of New Spain, begun by scholar and friar Bernardino de Sahagún in 1529.) Attempts, largely by missionaries, to suppress WISEMAN ADAM Peyote cacti at a plant nursery in Mexico.
    [Show full text]
  • (MDA); Research Reports Concerned with Clarif
    DOCUMENT RESUME ED 083 011 SE 016 838 TITLE National Clearinghouse for Drug Abuse Information Report Series, Series 25, No.1. INSTITUTION National Inst. of Mental Health (DHEW), Rockville, Md. National Clearinghouse for Drug Abuse Information. PUB DATE Oct 73 NOTE 9p. AVAILABLE FROM National Clearinghouse for Drug Abuse Information, 5600 Fishers Lane, Rockville, Maryland 20852 EDRS PRICE MF-$0.65 HC-$3.29 DESCRIPTORS Chemistry; *Drug Abuse; *Drug Education; Narcotics; Physiology; Reports; *Research; Social Sciences; *Stimulants IDENTIFIERS *Methylenedioxyamphetamine (MDA); Research Reports ABSTRACT Concerned with clarifying some of the more complex issues in drug abuse, the National Clearinghouse for Drug Abuse Information has preparedmthis special report on methylenedioxyamphetamine (MDA), commonly called Mellow Drug of America. Background information is provided through a summary of its history, legal status, and the opinions of authorities in the field. Significant research on the subject is presented together with major findings on various aspects of the problem. The pharmacology, chemistry, clinical effects (physiological, psychological, and subjective), and patterns of use of the drug are dealt with. Bibliographic references are also listed. (BL) FILMED FROM BEST AVAILABLE COPY- report series \tNiaMGH°usErZiafiSisE USDEPARTMENT CIF HEALTH, EDUCATION & WELFARE NATIONAL INSTITUTE OF EDUCATION YU'S DOCUMENT HAS BEEN REPRO DUCED EXACTLY AS RECEIVED FROM SERIES 25, NO.' 1 THE PERSON OR ORGANIZATION ORIGIN OCTOBER 1973 AT iNG POINTS OF VIEW OR OPINIONS STATED.'00 NOT NECECSARILY REPRE SENT OFFICIAL NATIONAL INSTITUTE OF EDUCATION POSITION OR POLICY The National Clearinghouse for Drug Abuse Information recognizes the need for clarifying some of the more complex issues in drug abuse by gathering the significant research findings on each subject and C_eveloping fact sheets on the problem.
    [Show full text]
  • Lysergic Acid Diethylamide (LSD)
    Lysergic Acid Diethylamide (LSD) DRUG CLASS: Psychedelics STREET NAMES: LSD, Acid, Paper, Sugar, Window Pane, Blotter, Illusion. WHAT IS IT? Synthetic hallucinogenic drugs that are made from a fungus. Psychedelics interfere with the normal brain chemistry. This drug triggers a wide range of changes in thought, perception, and behavior. Discovered in 1943 and widely used in the culture for young people in the 1960s, LSD has recently become popular in the 1990s. This is a chemical that is so strong that a single flake can cause actions similar to mental illness. There are many factors involved in the effects hallucinogens will have. For example, the size of the dose, emotional state of mind of the user, and the surroundings all play a role in determining whether the user has a good or bad "trip." A bad "trip" can include terrifying hallucinations, anxiety, fear of loss of control, paranoia, feeling all powerful and a sense that the high will never end. Someone with schizophrenic tendencies can have a really bad reaction to psychedelics, which would exaggerate those tendencies. WHAT CAN HAPPEN TO YOUR BODY? AT FIRST: • Changes in brain functioning. • Perceptual and thought distortions. • Hallucinations, skewed reality, and rapid mood swings. • Obsessive and negative thinking. • Heart beats faster. Blood pressure rises. • Body temperature rises. • Feel cold, shiver, get chills. • Can't see or hear well. • Get confused and panic. OVER TIME: • Permanent mental problems. • Difficulties interacting with others and distortions of perception and reality. • See things that aren't there (Hallucinations). • Severe depression. • Suicide. MEDICAL USES: None. Although LSD has been tried as a treatment for various forms of mental illness, the only currently approved research involving the drug is aimed at testing potential value as a treatment for drug dependence.
    [Show full text]
  • Hallucinogens Information for Health Professionals
    Hallucinogens Information for Health Professionals Introduction Hallucinogens are drugs that dramatically affect perception, emotions (mood), and mental processes (thought). They distort the senses and can cause hallucinations (seeing or hearing things that are not actually there); however, they usually cause lesser distortions of real objects and events. Since these disturbances of perception (visual hallucination) and behaviour cannot be classified as either sedative or stimulant effects, hallucinogens are sometimes called psychotomimetic. Hallucinogens, such as peyote and psilocybin, have been used in religious or spiritual ceremonies for thousands of years, dating back as far as 1600 BCE (Before Common Era). Hallucinogens continue to be used by some groups such as the Native American Church, which uses peyote as part of its spiritual practices. Although there was some interest during the 1960s and 1970s in the use of hallucinogens as an aid to psychiatric treatment, presently there is no accepted medical use for hallucinogens. Hallucinogens made synthetically include LSD, PCP and DMT. Some hallucinogens like MDA, MDMA (Ecstasy), and STP (DOM), have a chemical structure related to amphetamine. Hallucinogens derived from plants include mescaline from the peyote cactus, and psilocybin from “magic mushrooms”. Other plants containing hallucinogens include morning glory seeds, jimsonweed and nutmeg. Cannabis (marijuana) is not usually included in this group of drugs, but in very large dosage it can produce hallucinations. There is considerable deception in the sale of hallucinogens. Users can never be certain what drug or how much of a particular drug they are taking. For example, magic mushrooms sold by dealers are frequently cheaper, grocery-store varieties of mushrooms laced with LSD or PCP, and harmful synthetic hallucinogens are sold as LSD.
    [Show full text]
  • Alarming Trends in a Novel Class of Designer Drugs
    linica f C l To o x l ic a o n r l o u g o y J Grane et al. J Clinic Toxicol 2011, 1:2 Journal of Clinical Toxicology DOI: 10.4172/2161-0495.1000108 ISSN: 2161-0495 Research Article Article OpenOpen Access Access Alarming Trends in a Novel Class of Designer Drugs Owen Mc Grane*, Joshua Simmons, Eric Jacobson and Carl Skinner Department of Emergency Medicine, Madigan Army Medical Center, Tacoma, WA, USA Abstract Recent years have shown an increase in the use of the so-called “designer drugs.” This term is usually applied to recreational drugs that are new, synthetic and emerge as unscheduled drugs since they have not been in existence long enough to be illegal. These drugs are usually available at “head shops”, tobacco stores, gas stations and via the internet. Several such classes have gained increasing notoriety in the past 3-4 years, especially Spice and bath salts. One class that has gone almost unrecognized is the 2C class. The 2C’s are a class of synthetic hallucinogens known as phenethylamines, the same class as the naturally occurring drug mescaline. Few case reports of actual overdoses from 2C compounds have been reported, but some of the physical stigmata of use or overdose are thought to be pupil dilation, facial flushing, diaphoresis, bruxism, facial grimacing, tachycardia, tachypnea, emotional lability, and subjective symptoms such as accelerated internal clock, and detachment from surroundings. There are no known screening tests to easily detect the substance. However, it has been shown to be detected in rat urine using gas-chromatographic-mass spectrometry (GM-MS) as well as in human blood plasma using gas chromatography-mass spectrometry (GC-MS) and in human urine by capillary electrophoresis-MS [11,23].
    [Show full text]